enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Diabetes and obesity drugs fuel Eli Lilly profit in the final ...

   www.aol.com/diabetes-obesity-drugs-fuel-eli...

   Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast ...

3. Lilly rides wave of weight-loss drug demand, working to ... - AOL

   www.aol.com/news/lilly-sees-2024-profit-above...

   Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for Zepbound, its recently approved weight-loss drug, and said it would have new supply from expanded ...

4. Weight-loss drug drives Eli Lilly to raise 2024 sales ... - AOL

   www.aol.com/news/eli-lilly-lifts-profit-view...

   Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...

5. Diabetes and obesity drugs fuel Eli Lilly profit in the final ...

   lite.aol.com/news/health/story/0001/20250206/ca...

   Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...

6. Weight-loss drug powers Lilly results, 2024 forecast raised ...

   www.aol.com/news/eli-lilly-raises-annual-profit...

   Increased manufacturing capacity for Eli Lilly's highly sought after weight-loss drug Zepbound drove the company to raise its annual sales forecast by $3 billion on Thursday, and its share jumped ...

7. Why Eli Lilly Stock Popped on Thursday - AOL

   www.aol.com/finance/why-eli-lilly-stock-popped...

   Heading into the report, analysts forecast Lilly would earn $5.08 per share on sales of $13.4 billion. As it turns out, Lilly earned $5.32 per share in Q4, and sales were $13.5 billion. Why Eli ...

8. Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is ...

   www.aol.com/eli-lilly-shares-fall-glp-111700194.html

   Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

9. Eli Lilly reports mixed earnings, increases 2025 guidance

   www.aol.com/finance/eli-lilly-reports-mixed...

   Eli Lilly reported fourth quarter and full-year earnings for 2024 on Thursday.The results largely beat Wall Street estimates and sent the stock up about 2%. But the company missed on GLP-1 sales. ...